21-cfr-314-80

1 cases — ← All topics

Case Title Lower Court Docketed Status Flags Tags Question Presented
21-1238 Ina Ann Rodman v. Otsuka America Pharmaceutical, Inc. Ninth Circuit 2022-03-11 Denied Response Waived 21-cfr-314-80 design-defect drug-labeling expert-testimony failure-to-warn misbranding pharmaceutical-liability post-marketing-surveillance summary-judgment wyeth-v-levine 1. Whether Ms. Rodman presented admissible evidence in the form of Otsuka's failure to follow the admonition of 21 C.F.R. § 314.80 to conduct post-mar…